Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of Stock

Key Points

• United Therapeutics CFO James Edgemond sold 10,000 shares on April 13 at an average price of $574.88 for $5,748,800, leaving him with 18,876 shares—a disclosed 34.63% reduction in his position.
• The April 13 sale is part of a series of seven consecutive 10,000-share disposals between March 23 and April 13 (totaling 70,000 shares), indicating substantial insider selling over the period.
• UTHR shares traded near $578.54 with a $25.36 billion market cap, and analysts hold a Moderate Buy consensus with an average price target of $601.50 following a recent earnings beat.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the firm's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $10,851,434.88. The trade was a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Price Performance

NASDAQ UTHR traded up $0.91 during mid-day trading on Tuesday, reaching $578.54. 408,572 shares of the stock were exchanged, compared to its average volume of 497,478. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The stock has a 50 day simple moving average of $518.73 and a 200-day simple moving average of $486.05. The stock has a market cap of $25.36 billion, a P/E ratio of 20.74, a P/E/G ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the firm earned $6.19 earnings per share. United Therapeutics's quarterly revenue was up 7.4% on a year-over-year basis. Sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Weiss Ratings reissued a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. Morgan Stanley lifted their target price on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a research note on Friday. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 31st. Finally, Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday. They issued an "outperform" rating and a $700.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $601.50.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of the stock. Clearstead Advisors LLC grew its holdings in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after purchasing an additional 23 shares during the period. Independent Advisor Alliance grew its holdings in United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after purchasing an additional 27 shares during the period. Bessemer Group Inc. grew its holdings in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after purchasing an additional 28 shares during the period. Florida Financial Advisors LLC grew its holdings in United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company's stock worth $268,000 after purchasing an additional 28 shares during the period. Finally, NDVR Inc. grew its holdings in United Therapeutics by 5.1% in the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company's stock worth $300,000 after purchasing an additional 30 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.